Erstwhile GSK partner seeks to reassert its independence

20 September 2022

Less than two months after Theravance Biopharma (Nasdaq: TBPH) sold off rights to its share of royalties from parts of GSK’s (LSE: GSK) respiratory franchise, the company announced an agreement to buy back equity from the British drugmaker.

The purchase forms part of a strategy to move away from its legacy of respiratory products, developed together with GSK over many years, under a longstanding collaboration.

Theravance, which is listed in Dublin but based in California, agreed in July to sell rights to Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for over $1.5 billion in potential total value.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK